## Gaucher's Disease - Enzyme Replacement Prescriber Order Form

Oduciiei 3 Disease - Elizyilie Replacement i rescribei Ordei i o										Der Order Form	
То:			Phone:			Fax:			Date:		
From:			Phone: X		Fax:		# Pages, Incl. Co		ges, Incl. Cover:		
Patient Name:			Patier		Phone:					В:	
Address:		City:					State: Zip:		Zip:		
Primary Diagnosis											
_	☐ E75.21 - Fabry (Anderson) Disease ☐ E77.0 - Defects in Post-Translational Modification of Lysosomal Enzymes										
☐ E75.22 - Gaucher Disease ☐ E77.1 - Defects in Glycoprotein Degradation ☐ E75.249 - Niemann-Pick Disease, unspecified ☐ Other (ICD-10 Code and Description):											
In order to service your patient and facilitate insurance authorization, please complete the sections below:											
1	Ht: in cm Wt: lb kg Date:					☐ Date of first dose: ☐ Number of doses administered:					
	Attach Patient demographics, Insurance inf Medication list, and recent pertinent lab re	on, History and Ph	nysical,		Preferred site of administration:						
					☐ Patients Ho			Home			
2	Prescription:										
	☐ Cerezyme (imiglucerase) ☐ VPRIV (velaglucerase alfa)										
	Dose: 60 units/kg or units/kg IV every week(s).  (Dose will be round up to the nearest vial size)  Decline										
	Infusion Rate: Infuse in 100mls 0.9% NS over 60 minutes orminutes.  (Rate may be decreased in the event of an infusion related reaction.										
	Refills x										
3	Supporting Orders:  Acetaminophen 650 mgs orally 30 minutes before infusion.					Device	0.9% Sodium				
					Flush F	Protocol	Chloride Flush			Heparin	
	☐ Diphenhydramine 25 mgs orally 30 minutes before infusion.				Perip	heral	2 - 3 ml pre/post use			1 - 3 ml (10 units/ml) post use; maintenance q24hr	
	☐ Methylprednisolone 40 mgs IVP 20 min	efore infusion.		Peripl	heral-	3 - 5 ml pre/post use;		3	ml (100 units/ml) post use;		
	Other:					lline	5 ml pre/10 ml post lab draw			maintenance q24hr	
	<ul> <li>Anaphylaxis: Stop infusion, Call EMS, Give epinephrine 0.3 mg diphenhydramine 25 - 50 mg oral/injectable, 0.9% Sodium Chlo mls per hour bag as needed per symptoms. Call prescriber.</li> </ul>				PICC &	Central	d & 5 ml pre/post use;		3 ml (heparin 100 units/ml) or 5 ml (10 units/ml) post use; maintenance q24hr		
				_		eled & inneled					
	If applicable, flush intravenous access device per instructions in chart.      The state of								- (	3 - 5 ml (100 units/ml) post	
	<ul> <li>When appropriate: Provide infusion pump(s) and supplies n administer therapy and skilled nurse to administer doses in</li> </ul>			Im		anted	5 - 10 ml pre/post use;		us	se; maintenance if accessed 3 - 5 ml q24hr or if not	
	home/alternate care setting via vascular access		s device.		Po	ort	10 - 20 ml p	10 - 20 ml pre/post lab draw		accessed 3 - 5 ml weekly to monthly	
	<ul> <li>Refill ancillary medications x 1 year.</li> <li>*Liquid dosage form in appropriate cond</li> </ul>	on/amount may b	/amount may be		alved	5 - 10 ml pre/post use;		Thornally			
	dispensed upon patient request.					heters: 10 - 20 ml j		ore/post lab draw;		N/A	
					Chest, Mid	lline	maintenance 5 - 10 ml weekly		St		
4	Lab and Other Orders:						I				
										_	
I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.											
Prescriber Signature: Date:											
Ph	ysician Name:										
Ad	dress:	Office Contact:									
Cit	y: S										
Phone: Fax:											
	IFIDENTIAL HEALTH INFORMATION: Healthcare information is personal										
maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is profibiled unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is most the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is											
STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.											
ا م	Local Contact Information:										

Fax to: \_\_\_\_\_